Literature DB >> 29179185

VEGF-A/Neuropilin 1 Pathway Confers Cancer Stemness via Activating Wnt/β-Catenin Axis in Breast Cancer Cells.

Lansheng Zhang1, Hongmei Wang2, Caihong Li1, Yang Zhao2, Langjie Wu2, Xiuping Du2, Zhengxiang Han2.   

Abstract

BACKGROUND/AIMS: Targeting cancer stem cells (CSCs) is emerging as a promising method for cancer treatment. We previously indicated that knockdown of Neuropilin 1(NRP-1) could inhibit breast cancer cell proliferation. Here, we continue exploring the roles and mechanisms of VEGF-A/NRP-1 axis in breast CSCs formation.
METHODS: qRT-PCR was used to detect the levels of VEGF-A and NRP-1 in breast cancer sphere cells and wild-type cells. Mammospheres formation, flow cytometry, soft agar colony and tumor formation assays were performed to evaluate the effects of VEGF-A/NRP-1 on breast cancer stemness. Further HUVECs tube formation, cell invasion assays were carried out to detect the effects of VEGF-A/NRP-1 on breast cancer spheres-induced angiogenesis. Finally, Annexin V/PI apoptosis and CCK8 assays were used to detect the effects of VEGF-A/NRP-1 on chemoresistance.
RESULTS: Overexpression of VEGF-A or NRP-1 conferred CSCs-related traits in MCF-7 cells, while knockdown of VEGF-A or NRP-1 reduced CSCs-related traits in MDA-MB-231 cells in vitro and in vivo. Notably, VEGF-A acted in a NRP-1 dependent way. Mechanistically, the VEGF-A/NRP-1 axis conferred CSCs phenotype via activating Wnt/β-catenin pathway.
CONCLUSION: our results suggest that VEGF-A/NRP-1 axis could confer CSCs-related traits and chemoresistance.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Nrp-1; VEGF-A; Wnt/β-catenin CSCs breast cancer doxorubicin

Mesh:

Substances:

Year:  2017        PMID: 29179185     DOI: 10.1159/000485455

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  23 in total

1.  [Vascular endothelial growth factor promotes cancer stemness of triple-negative breast cancer via MAPK/ERK pathway].

Authors:  L Wang; L Zhao; L Zhang; X Jing; Y Zhang; S Shao; X Zhao; M Luo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

2.  Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway.

Authors:  Wei Xie; Yan Zhang; Shiwei Zhang; Fengxian Wang; Kunchi Zhang; Yanjuan Huang; Zhaoli Zhou; Gang Huang; Jin Wang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

3.  FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.

Authors:  Shaoqiang Cheng; Yuanxi Huang; Chun Lou; Yanxia He; Yue Zhang; Qingyuan Zhang
Journal:  Cancer Biol Ther       Date:  2018-10-18       Impact factor: 4.742

Review 4.  Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy.

Authors:  Chryso Kanthou; Gillian Tozer
Journal:  Br J Radiol       Date:  2018-09-05       Impact factor: 3.039

5.  Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases.

Authors:  Navatha Shree Polavaram; Samikshan Dutta; Ridwan Islam; Arup K Bag; Sohini Roy; David Poitz; Jeffrey Karnes; Lorenz C Hofbauer; Manish Kohli; Brian A Costello; Raffael Jimenez; Surinder K Batra; Benjamin A Teply; Michael H Muders; Kaustubh Datta
Journal:  Bone Res       Date:  2021-05-14       Impact factor: 13.567

Review 6.  Vascular Endothelial Growth Factor-A Exerts Diverse Cellular Effects via Small G Proteins, Rho and Rap.

Authors:  Akio Shimizu; Dimitar P Zankov; Misuzu Kurokawa-Seo; Hisakazu Ogita
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

7.  miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR.

Authors:  Lansheng Zhang; Yanwei Chen; Hui Wang; Xia Zheng; Caihong Li; Zhengxiang Han
Journal:  Onco Targets Ther       Date:  2018-08-30       Impact factor: 4.147

Review 8.  Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.

Authors:  Manon Douyère; Pascal Chastagner; Cédric Boura
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

Review 9.  Targeting VEGF/VEGFR to Modulate Antitumor Immunity.

Authors:  Ju Yang; Jing Yan; Baorui Liu
Journal:  Front Immunol       Date:  2018-05-03       Impact factor: 7.561

10.  NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.

Authors:  Concetta Saponaro; Alessandro Vagheggini; Emanuela Scarpi; Matteo Centonze; Ivana Catacchio; Ondina Popescu; Maria Irene Pastena; Francesco Giotta; Nicola Silvestris; Anita Mangia
Journal:  J Exp Clin Cancer Res       Date:  2018-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.